{ "schemaVersion": 2, "eyebrow": "Obstetric hemorrhage", "title": "Postpartum Hemorrhage Treatment Sequence", "summary": "Treat postpartum hemorrhage as simultaneous resuscitation and source control: quantify loss, assess tone, trauma, tissue, and thrombin, give early tranexamic acid, escalate rapidly from uterotonics to tamponade or operative control, and replace fibrinogen before severe coagulopathy develops.", "seoDescription": "A practical postpartum hemorrhage treatment sequence: resuscitation, tranexamic acid, uterotonics, tamponade, transfusion targets, and surgical escalation.", "clinicalQuestion": "What is the practical treatment sequence for postpartum hemorrhage from recognition through definitive hemorrhage control?", "specialty": "Obstetrics and Gynecology", "audience": "U.S. physicians and medical trainees", "tags": [ "postpartum hemorrhage", "PPH management", "uterine atony", "tranexamic acid", "Bakri balloon", "massive transfusion", "obstetric hemorrhage" ], "keyTakeaways": [ "Do not wait for a fixed blood-loss threshold when bleeding is abnormal or hemodynamic signs appear; cumulative blood loss of at least 1,000 mL with hypovolemia within 24 hours meets the contemporary PPH definition. [20]", "Activate parallel hemorrhage management: quantify loss, obtain CBC, platelet count, coagulation studies, and fibrinogen, establish resuscitation access, and identify the bleeding source using the 4 Ts. [18][20]", "Give intravenous tranexamic acid as soon as PPH is diagnosed and within 3 hours of birth, in addition to standard care. [13]", "For uterine atony, proceed from uterine massage and oxytocin to a nonredundant uterotonic; carboprost is 250 micrograms IM every 15-30 minutes when appropriate, with asthma as a relative contraindication. [7]", "Ongoing severe bleeding requires early mechanical or operative source control rather than serial medication trials: intrauterine balloon tamponade, compression sutures, uterine devascularization or embolization, then hysterectomy when bleeding remains uncontrolled. [6][8]", "Check fibrinogen early in severe PPH; a level below 2 g/L predicts progression to severe bleeding and warrants fibrinogen replacement, with a target of at least 150-200 mg/dL during massive transfusion. [21][22]" ], "sections": [ { "id": "recognize-and-activate", "eyebrow": "First minutes", "heading": "Recognize abnormal bleeding and activate the hemorrhage response", "intro": "Management begins before conventional volume criteria are reached when bleeding is clinically concerning.", "paragraphs": [ "Use quantitative blood-loss measurement rather than visual estimation, and treat continued abnormal bleeding with any hemodynamic deterioration as an obstetric emergency. A cumulative blood loss of 1,000 mL or more accompanied by signs or symptoms of hypovolemia within 24 hours after birth defines PPH regardless of delivery route; primary PPH occurs within 24 hours, whereas secondary PPH occurs from 24 hours to 6-12 weeks postpartum. [1][20]", "At recognition, call obstetric anesthesia, the blood bank, and senior obstetric support; establish resuscitation and initiate the institutional massive-transfusion pathway if bleeding is rapid or ongoing. Care bundles using quantitative measurement, senior escalation at 1,000 mL and 1,500 mL, point-of-care hemostasis testing at 1,000 mL or more, and early tranexamic acid were associated with less progression to severe PPH of at least 2,500 mL and fewer transfusions. [18]", "Obtain a CBC with platelet count, fibrinogen, and coagulation testing while treatment proceeds; do not defer source control pending results. In severe ongoing PPH, standard fibrinogen testing or viscoelastic testing with ROTEM or TEG provides earlier actionable assessment of hypofibrinogenemia than waiting for later clinical coagulopathy. [19][20][21]" ], "bullets": [ "Document quantified cumulative loss and reassess uterine tone, vaginal/perineal bleeding, and hemodynamics after every intervention. [18][20]", "Warm the patient and monitor acid-base status and calcium during major transfusion because citrate-related hypocalcemia can impair coagulation and uterine contraction. [21]", "Use point-of-care coagulation testing only where trained staff and quality-control processes are available. [19]" ], "subsections": [], "table": { "caption": "Escalation triggers for immediate postpartum hemorrhage response. [18][20]", "columns": [ "Finding", "Interpretation", "Immediate next action" ], "rows": [ [ "Abnormal postpartum bleeding with hemodynamic signs", "Treat as clinically significant hemorrhage even before 1,000 mL cumulative loss. [20][24]", "Activate PPH response; begin source assessment and resuscitation simultaneously. [20]" ], [ "Cumulative blood loss at least 1,000 mL", "Threshold for senior escalation and point-of-care hemostasis assessment in a structured bundle. [18]", "Escalate to senior clinicians, obtain fibrinogen/coagulation assessment, and prepare blood products. [18][21]" ], [ "Cumulative blood loss at least 1,500 mL or rapidly ongoing bleeding", "High-risk trajectory requiring intensified multidisciplinary response. [18]", "Activate or intensify massive-transfusion and definitive hemorrhage-control planning. [18][21]" ], [ "Fibrinogen below 2 g/L", "Early predictor of progression to severe bleeding. [21]", "Replace fibrinogen with cryoprecipitate or fibrinogen concentrate according to local protocol. [21][22]" ] ] } }, { "id": "identify-the-source", "eyebrow": "Parallel assessment", "heading": "Use the 4 Ts to choose source-directed treatment", "intro": "Atony is common, but persistent bleeding despite a firm uterus requires immediate source reassessment.", "paragraphs": [ "Perform a focused 4 Ts assessment during resuscitation: Tone (uterine atony), Trauma (laceration, hematoma, uterine rupture or inversion), Tissue (retained products or abnormal placentation), and Thrombin (acquired or inherited coagulopathy). Uterine atony is the most common cause of primary PPH, but trauma, retained tissue, and coagulopathy require fundamentally different interventions. [20][14][15]", "A boggy, enlarged uterus supports atony and warrants uterine massage, bimanual compression, and uterotonics. Continued brisk bleeding with a firm contracted uterus should prompt inspection for cervical, vaginal, perineal, or operative-site trauma; assess for concealed puerperal genital hematoma when pain, pressure, or hemodynamic compromise exceeds visible blood loss. [8][15]", "If placental delivery is incomplete, bleeding persists with suspected retained tissue, or delayed hemorrhage develops, evaluate for retained or residual products of conception. Secondary hemorrhage is commonly associated with retained products, infection, subinvolution of the placental site, lacerations, uterine atony, and inherited coagulation disorders; pelvic imaging can help define retained products, hematoma, uterine dehiscence, or other structural causes. [1][14][15]" ], "bullets": [ "Tone: massage, bimanual compression, uterotonics, then tamponade or operative uterine compression when bleeding persists. [7][8]", "Trauma: expose and repair lacerations; do not expect uterotonics to control bleeding from a genital tract injury. [15]", "Tissue: remove retained tissue when identified and plan early multidisciplinary hemorrhage control for placenta accreta spectrum or placenta previa-associated bleeding. [5][14]", "Thrombin: obtain fibrinogen, platelet count, and coagulation studies early; replace deficits while treating the anatomic source. [20][21][22]" ], "subsections": [], "table": { "caption": "Etiologic branch points that change postpartum hemorrhage treatment. [8][14][15][20]", "columns": [ "Branch", "Bedside discriminator", "Treatment direction" ], "rows": [ [ "Tone", "Boggy or poorly contracted uterus. [20]", "Uterine massage and bimanual compression; administer uterotonics; escalate promptly to balloon tamponade or uterine compression procedures if refractory. [7][8]" ], [ "Trauma", "Persistent bleeding despite a firm uterus; visible laceration or suspected hematoma. [15]", "Identify and repair the injury; evaluate structural complications such as rupture or dehiscence when indicated. [15]" ], [ "Tissue", "Incomplete placenta, suspected retained products, or bleeding associated with abnormal placentation. [1][14]", "Address retained tissue and use multidisciplinary operative planning for placenta accreta spectrum or placenta previa-associated hemorrhage. [5][14]" ], [ "Thrombin", "Low fibrinogen, thrombocytopenia, abnormal coagulation testing, or bleeding disproportionate to local findings. [20][21]", "Deliver targeted blood-component therapy while continuing mechanical or surgical hemostasis. [21][22]" ] ] } }, { "id": "medical-treatment", "eyebrow": "Medication sequence", "heading": "Treat uterine atony with simultaneous antifibrinolytic therapy and uterotonics", "intro": "Medication should occur while the uterus is assessed and mechanical escalation is prepared.", "paragraphs": [ "For suspected atony, begin uterine massage and bimanual compression with oxytocin-based uterotonic treatment. If bleeding continues, select an additional uterotonic with a different mechanism rather than repeating ineffective treatment; the choice depends on contraindications and the clinical speed of hemorrhage. [7][8]", "Administer intravenous tranexamic acid as soon as PPH is diagnosed and within 3 hours after birth, as an adjunct to standard PPH treatment rather than as a substitute for uterotonics, repair, tamponade, transfusion, or surgery. In structured treatment bundles, tranexamic acid was given upon recognition of abnormal bleeding and repeated if bleeding continued. [13][18]", "Carboprost is a practical second-line uterotonic for refractory atony after uterine massage and oxytocin when methylergonovine is ineffective or contraindicated. Give 250 micrograms intramuscularly and repeat every 15-30 minutes as needed; avoid or use exceptional caution in asthma because bronchospasm risk makes asthma a relative contraindication. [7]" ], "bullets": [ "Do not continue a medication-only sequence when bleeding remains brisk after initial uterotonic treatment; move to tamponade or operative control while blood products are mobilized. [6][8]", "Use clinical response—uterine tone and bleeding rate—not elapsed time alone—to determine whether atony treatment has failed. [7][8]", "When a nonatony source is identified, direct treatment to that source even if uterotonics have already been administered. [8][15]" ], "subsections": [], "table": { "caption": "Medication choices supported for the early atony branch. [7][13][18]", "columns": [ "Intervention", "When to use", "Dose or timing", "Key limitation" ], "rows": [ [ "Uterine massage and bimanual compression", "Immediate intervention for suspected uterine atony. [7][8]", "Initiate immediately while uterotonics and source assessment proceed. [7][8]", "Insufficient alone in refractory hemorrhage. [8]" ], [ "Oxytocin", "First-line medication used with uterine massage for atony. [7]", "Use per institutional obstetric hemorrhage protocol; a dose was not specified in the cited material. [7]", "Persistent bleeding requires an additional uterotonic or mechanical escalation. [7][8]" ], [ "Tranexamic acid", "Adjunct once PPH is diagnosed. [13]", "Intravenous administration as soon as diagnosed and within 3 hours of birth. [13]", "Does not replace anatomic source control. [13][18]" ], [ "Carboprost", "Refractory atony after massage and oxytocin, especially when methylergonovine is ineffective or unsuitable. [7]", "250 micrograms IM; repeat every 15-30 minutes as needed. [7]", "Asthma is a relative contraindication. [7]" ] ] } }, { "id": "mechanical-and-operative-escalation", "eyebrow": "Source control", "heading": "Escalate rapidly from tamponade to vascular control or hysterectomy", "intro": "Persistent hemorrhage after initial medical therapy is an indication for procedural control, not prolonged observation.", "paragraphs": [ "For refractory uterine bleeding after uterotonics, use intrauterine balloon tamponade as an early uterus-preserving mechanical option when the uterus is the likely bleeding source. Failure of tamponade, uncontrolled bleeding, or concern for a surgical source should prompt operative escalation without delay. [6][8]", "Uterus-preserving operative options include uterine compression sutures such as B-Lynch, Hayman, or Cho techniques; uterine artery ligation; stepwise uterine devascularization; internal iliac artery ligation; and selective arterial embolization. Selection depends on delivery route, bleeding site and volume, hemodynamic tolerance, and immediate technical and personnel availability. [6][8]", "Arterial embolization can preserve reproductive function but requires a stable enough patient, immediate interventional radiology capability, and no delay in control of exsanguinating hemorrhage. High-risk patients, particularly those with placenta accreta spectrum or placenta previa, should be managed at centers with 24-hour multidisciplinary and interventional radiology resources when feasible. [5][6]", "Proceed to peripartum hysterectomy when conservative medical, mechanical, and vascular-control measures cannot achieve hemostasis or when the clinical situation makes fertility-preserving approaches unsafe. In a tertiary-center series of PPH requiring massive-transfusion protocol activation, 19% underwent peripartum hysterectomy and 61% required ICU admission, underscoring the need to avoid delayed escalation. [4]" ], "bullets": [ "Use balloon tamponade as a therapeutic maneuver for uterine-source bleeding after failed uterotonics. [6][8]", "Choose compression sutures or uterine devascularization when laparotomy is already underway or immediate surgical control is required. [6][8]", "Choose uterine artery embolization when bleeding is ongoing but time, stability, and interventional radiology access permit transfer to angiography without compromising definitive control. [5][6]", "Do not defer hysterectomy for sequential conservative procedures in rapidly deteriorating or uncontrolled hemorrhage. [4][8]" ], "subsections": [], "table": { "caption": "Procedure selection after failed initial uterotonic management. [5][6][8]", "columns": [ "Procedure", "Best-fit clinical circumstance", "Practical tradeoff" ], "rows": [ [ "Intrauterine balloon tamponade", "Refractory uterine bleeding when a uterus-preserving mechanical intervention is appropriate. [6][8]", "Can avert laparotomy, but failure requires prompt progression to operative or vascular control. [6][8]" ], [ "Uterine compression sutures", "Persistent atony requiring operative management, particularly when laparotomy is available. [6][8]", "May preserve fertility but requires surgical expertise and does not address unrecognized trauma or retained tissue. [6][8]" ], [ "Uterine or internal iliac artery ligation / devascularization", "Ongoing surgical hemorrhage requiring vascular reduction. [6][8]", "Provides immediate operative control but requires technical expertise. [6][8]" ], [ "Selective arterial embolization", "Persistent hemorrhage in a patient for whom angiographic management can be performed without dangerous delay. [5][6]", "Potentially fertility-preserving; dependent on interventional radiology access and patient stability. [5][6]" ], [ "Peripartum hysterectomy", "Uncontrolled life-threatening hemorrhage after failed conservative measures or when conservative treatment is unsafe. [4][8]", "Definitive hemostasis at the cost of fertility. [4][8]" ] ] } }, { "id": "transfusion-and-hemostasis", "eyebrow": "Hemostatic resuscitation", "heading": "Replace blood components early and target fibrinogen during severe hemorrhage", "intro": "Transfusion is supportive until source control is achieved; its purpose is to maintain oxygen delivery and correct evolving coagulopathy.", "paragraphs": [ "During severe ongoing PPH, monitor fibrinogen early because it is the first coagulation factor to fall to critical levels. A fibrinogen concentration below 2 g/L has been reported to predict progression to severe bleeding, and values below 200 mg/dL are an indication for component replacement; target at least 150-200 mg/dL during massive transfusion. [21][22]", "Use cryoprecipitate or fibrinogen concentrate according to the institution's PPH protocol and product availability. A usual cryoprecipitate dose of 10 units is estimated to increase fibrinogen by approximately 100 mg/dL, but repeat laboratory or viscoelastic assessment should determine whether the target has been achieved. [22]", "When hemorrhage is massive, activate a ratio-driven blood-product protocol rather than waiting for isolated laboratory abnormalities; published obstetric protocols use RBC:FFP:platelet ratios of 6:4:1, 4:4:1, or 1:1:1, although these ratios are extrapolated from trauma literature and no single obstetric ratio is established. [21]", "In the nonmassively bleeding phase, a restrictive RBC transfusion threshold of hemoglobin below 7 g/dL is preferred. With active bleeding, RBC transfusion thresholds may shift to hemoglobin 7-9 g/dL depending on local protocol and maternal comorbidity; continue to correct hypothermia, acid-base derangement, and citrate-associated hypocalcemia during major transfusion. [21]" ], "bullets": [ "Obtain fibrinogen early in severe PPH; do not rely on hemoglobin alone to detect impending coagulopathy. [21][22]", "Use ROTEM or TEG to guide targeted replacement when available and interpreted by trained clinicians. [19][21]", "Reassess bleeding source after each transfusion cycle; worsening laboratory values without source control require procedural escalation. [21]" ], "subsections": [], "table": { "caption": "Laboratory-guided hemostatic decisions in severe postpartum hemorrhage. [21][22][23]", "columns": [ "Parameter", "Actionable result", "Treatment implication" ], "rows": [ [ "Plasma fibrinogen", "Below 2 g/L predicts progression to severe bleeding; below 200 mg/dL indicates component replacement. [21][22]", "Give cryoprecipitate or fibrinogen concentrate and target at least 150-200 mg/dL. [22]" ], [ "ROTEM FIBTEM A5", "A5 of 12 mm or less had a positive predictive value of 22.5% for progression to severe PPH. [23]", "Use within a trained, protocolized viscoelastic-testing pathway to guide early fibrinogen-focused therapy. [19][23]" ], [ "Hemoglobin during nonmassive bleeding", "Below 7 g/dL. [21]", "Use restrictive RBC transfusion strategy if not actively massively bleeding. [21]" ], [ "Hemoglobin during active bleeding", "7-9 g/dL may be used depending on local protocol and maternal conditions. [21]", "Transfuse in the context of active loss, physiology, and concurrent component replacement. [21]" ] ] } }, { "id": "secondary-hemorrhage", "eyebrow": "Delayed bleeding", "heading": "Evaluate secondary postpartum hemorrhage for retained tissue, infection, or vascular injury", "intro": "Bleeding beginning after the first 24 hours follows a different diagnostic branch than immediate atony.", "paragraphs": [ "For hemorrhage from 24 hours through 6-12 weeks postpartum, first reassess hemodynamic status and quantify active loss, then prioritize retained products of conception, infection, subinvolution of the placental site, laceration, uterine atony, and inherited coagulation disorders. This timing distinction matters because delayed bleeding should not be presumed to be uncomplicated uterine atony. [1][20]", "Use pelvic imaging when the clinical assessment suggests retained products, genital tract hematoma, uterine rupture or dehiscence, or another structural source. Imaging is particularly useful when bleeding persists despite initial bedside assessment or when the source is not visible on examination. [14][15]", "If secondary hemorrhage is hemodynamically significant, initiate the same resuscitation, blood-bank, and hemostatic pathway used for primary PPH while arranging source-directed treatment. Delayed presentation does not reduce the need for urgent fibrinogen assessment and procedural escalation when bleeding is severe. [1][21]" ], "bullets": [ "Retained or residual products on clinical or imaging evaluation direct management toward uterine source control rather than repeated empiric uterotonics. [14][15]", "Pain or pressure with disproportionate shock should raise concern for a concealed genital tract hematoma. [15]", "Suspected coagulopathy warrants CBC, platelet count, coagulation testing, and fibrinogen assessment during active hemorrhage. [20][21]" ], "subsections": [], "table": { "caption": "Secondary postpartum hemorrhage branch points. [1][14][15][20]", "columns": [ "Pattern", "Likely concern", "Next step" ], "rows": [ [ "Bleeding 24 hours to 6-12 weeks after birth", "Secondary PPH. [1][20]", "Reassess hemodynamics and evaluate tissue, infection, trauma, and coagulation causes. [1][20]" ], [ "Persistent bleeding with suspected intrauterine source", "Retained or residual products of conception. [14][15]", "Use pelvic imaging and arrange source-directed uterine management. [14][15]" ], [ "Pain, pressure, or shock exceeding visible blood loss", "Puerperal genital hematoma or other concealed trauma. [15]", "Perform targeted examination and imaging for structural injury. [15]" ], [ "Bleeding with abnormal hemostatic testing", "Coagulopathy contributing to ongoing hemorrhage. [20][21]", "Replace deficits, especially fibrinogen, while controlling the anatomic source. [21][22]" ] ] } } ], "faq": [], "references": [ { "number": 1, "title": "Team-Based Care of Women With Cardiovascular Disease From Pre-Conception Through Pregnancy and Postpartum: JACC Focus Seminar 1/5", "detail": "www.jacc.org", "url": "https://www.jacc.org/doi/10.1016/j.jacc.2021.02.033", "authors": "www.jacc.org", "host": "www.jacc.org" }, { "number": 2, "title": "Point-of-Care Fibrinogen Testing and Hemorrhage...", "detail": "journals.lww.com", "url": "https://journals.lww.com/00060825-202609000-00009", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 3, "title": "Massive obstetric hemorrhage: Current approach to management - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S2173572716300212", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 4, "title": "Postpartum hemorrhage treated with a massive transfusion protocol at a tertiary obstetric center: a retrospective study - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S0959289X12000441", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 5, "title": "Prophylactic interventional radiological... : The Indian Anaesthetists Forum", "detail": "journals.lww.com", "url": "https://journals.lww.com/iaaf/fulltext/2021/22010/prophylactic_interventional_radiological.3.aspx", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 6, "title": "Medical and Conservative Surgical Management of Postpartum Hemorrhage - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S1701216316302419", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 7, "title": "Carboprost - an overview | ScienceDirect Topics", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/topics/medicine-and-dentistry/carboprost", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 8, "title": "Management of intractable postpartum haemorrhage... : Nigerian Medical Journal", "detail": "journals.lww.com", "url": "https://journals.lww.com/nimj/fulltext/2012/53020/management_of_intractable_postpartum_haemorrhage.6.aspx", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 9, "title": "Postpartum haemorrhage in high‐resource settings: Variations in clinical management and future research directions based on a comparative study of national guidelines - Vries - 2023 - BJOG: An International Journal of Obstetrics & Gynaecology - Wiley Online Library", "detail": "obgyn.onlinelibrary.wiley.com", "url": "https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.17551", "authors": "obgyn.onlinelibrary.wiley.com", "host": "obgyn.onlinelibrary.wiley.com" }, { "number": 10, "title": "Tranexamic acid for preventing postpartum blood loss after ...", "detail": "obgyn.onlinelibrary.wiley.com", "url": "https://obgyn.onlinelibrary.wiley.com/doi/10.1111/aogs.12798", "authors": "obgyn.onlinelibrary.wiley.com", "host": "obgyn.onlinelibrary.wiley.com" }, { "number": 11, "title": "The Use of Tranexamic Acid to Prevent Postpartum ...", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/full/10.1111/jmwh.13101", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com" }, { "number": 12, "title": "Women receiving massive transfusion due to postpartum ...", "detail": "obgyn.onlinelibrary.wiley.com", "url": "https://obgyn.onlinelibrary.wiley.com/doi/10.1111/aogs.13542", "authors": "obgyn.onlinelibrary.wiley.com", "host": "obgyn.onlinelibrary.wiley.com" }, { "number": 13, "title": "FIGO recommendations on the management of postpartum ...", "detail": "obgyn.onlinelibrary.wiley.com", "url": "https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116", "authors": "obgyn.onlinelibrary.wiley.com", "host": "obgyn.onlinelibrary.wiley.com" }, { "number": 14, "title": "Secondary Postpregnancy Hemorrhage: Guide for Diagnosis and ...", "detail": "pubs.rsna.org", "url": "https://pubs.rsna.org/doi/10.1148/rg.240098", "authors": "pubs.rsna.org", "host": "pubs.rsna.org" }, { "number": 15, "title": "Imaging of Antepartum and Postpartum Hemorrhage - RSNA Journals", "detail": "pubs.rsna.org", "url": "https://pubs.rsna.org/doi/10.1148/rg.230164", "authors": "pubs.rsna.org", "host": "pubs.rsna.org" }, { "number": 16, "title": "Imaging of Antepartum and Postpartum Hemorrhage", "detail": "pubs.rsna.org", "url": "https://pubs.rsna.org/doi/abs/10.1148/rg.230164", "authors": "pubs.rsna.org", "host": "pubs.rsna.org" }, { "number": 17, "title": "Interventional Radiology and Pregnancy: From Conception ...", "detail": "pubs.rsna.org", "url": "https://pubs.rsna.org/doi/pdf/10.1148/rg.230029", "authors": "pubs.rsna.org", "host": "pubs.rsna.org" }, { "number": 18, "title": "Evidence-to-decision framework: treatment bundles for postpartum haemorrhage - WHO recommendations on the assessment of postpartum blood loss and use of a treatment bundle for postpartum haemorrhage - NCBI Bookshelf", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK598983", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov" }, { "number": 19, "title": "Haemostatic monitoring during postpartum haemorrhage and implications for management - PMC", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3498756", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 20, "title": "Postpartum Hemorrhage - StatPearls - NCBI Bookshelf - NIH", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK499988", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov" }, { "number": 21, "title": "Management of Postpartum Haemorrhage", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9885818", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 22, "title": "FIGO recommendations on the management of postpartum ... - PMC", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9313855", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 23, "title": "Clinical value of early viscoelastometric point‐of‐care testing during ...", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8453832", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 24, "title": "Recommendations and supporting evidence - Consolidated guidelines for the prevention, diagnosis and treatment of postpartum haemorrhage - NCBI Bookshelf", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK619233", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov" } ], "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.", "citations": [ { "number": 1, "title": "Team-Based Care of Women With Cardiovascular Disease From Pre-Conception Through Pregnancy and Postpartum: JACC Focus Seminar 1/5", "detail": "www.jacc.org", "url": "https://www.jacc.org/doi/10.1016/j.jacc.2021.02.033", "authors": "www.jacc.org", "host": "www.jacc.org", "snippet": "measurement within 3 days is imperative for women with and at risk for hypertensive complications. The American College of Obstetricians and Gynecologists (ACOG) guidelines support an initial postpartum assessment within the first 3 weeks postpartum with interim follow-up as needed and a comprehensi", "score": 0.39564833 }, { "number": 2, "title": "Point-of-Care Fibrinogen Testing and Hemorrhage...", "detail": "journals.lww.com", "url": "https://journals.lww.com/00060825-202609000-00009", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "In that definition, blood loss of at least 1000 mL is considered a key diagnostic indicator of clinically significant postpartum hemorrhage; this volume is", "score": 0.62770075 }, { "number": 3, "title": "Massive obstetric hemorrhage: Current approach to management - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S2173572716300212", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "# Massive obstetric hemorrhage: Current approach to managementHemorragia masiva obstétrica: enfoque terapéutico actual☆. Massive obstetric hemorrhage is a major cause of maternal mortality and morbidity worldwide. Optimization, preparation, rational use of resources and protocolization of actions ar", "score": 0.5697814 }, { "number": 4, "title": "Postpartum hemorrhage treated with a massive transfusion protocol at a tertiary obstetric center: a retrospective study - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S0959289X12000441", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "## International Journal of Obstetric Anesthesia. Volume 21, Issue 3, July 2012, Pages 230-235. # ORIGINAL ARTICLE Postpartum hemorrhage treated with a massive transfusion protocol at a tertiary obstetric center: a retrospective study. Author links open overlay panel, , ,. ## Abstract. ### Backgroun", "score": 0.568632 }, { "number": 5, "title": "Prophylactic interventional radiological... : The Indian Anaesthetists Forum", "detail": "journals.lww.com", "url": "https://journals.lww.com/iaaf/fulltext/2021/22010/prophylactic_interventional_radiological.3.aspx", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "Title: Prophylactic interventional radiological... : The Indian Anaesthetists Forum\n# Prophylactic interventional radiological procedures in postpartum hemorrhage. Patients at increased risk for PPH should be referred to tertiary care centers equipped with interventional radiology suite, where multi", "score": 0.7625837 }, { "number": 6, "title": "Medical and Conservative Surgical Management of Postpartum Hemorrhage - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S1701216316302419", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "Title: Medical and Conservative Surgical Management of Postpartum Hemorrhage - ScienceDirect\n# Medical and Conservative Surgical Management of Postpartum Hemorrhage. Massive postpartum hemorrhage (PPH) is a major cause of maternal mortality in the United Kingdom and worldwide. The less radical surgi", "score": 0.7283819 }, { "number": 7, "title": "Carboprost - an overview | ScienceDirect Topics", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/topics/medicine-and-dentistry/carboprost", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "Carboprost, an analog of prostaglandin F2α, has an important role in the management of refractory uterine atony. When first-line treatment with manual uterine massage and oxytocin has failed, and methylergonovine is contraindicated or has not been effective, it is imperative that uterine tone be res", "score": 0.6889923 }, { "number": 8, "title": "Management of intractable postpartum haemorrhage... : Nigerian Medical Journal", "detail": "journals.lww.com", "url": "https://journals.lww.com/nimj/fulltext/2012/53020/management_of_intractable_postpartum_haemorrhage.6.aspx", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "hemorrhage is defined as the hemorrhage after 24 hours of delivery. In our unit, standard management for PPH included uterine massage, bimanual compression, and medication with oxytocin or analogs of prostaglandins E1 in selected cases. If these therapies failed to stop the bleeding, surgical treatm", "score": 0.6519982 }, { "number": 9, "title": "Postpartum haemorrhage in high‐resource settings: Variations in clinical management and future research directions based on a comparative study of national guidelines - Vries - 2023 - BJOG: An International Journal of Obstetrics & Gynaecology - Wiley Online Library", "detail": "obgyn.onlinelibrary.wiley.com", "url": "https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.17551", "authors": "obgyn.onlinelibrary.wiley.com", "host": "obgyn.onlinelibrary.wiley.com", "snippet": "10.1093/bja/aes096CAS PubMed Web of Science® Google Scholar\n 56Ahmed S, Harrity C, Johnson S, Varadkar S, McMorrow S, Fanning R, et al. The efficacy of fibrinogen concentrate compared with cryoprecipitate in major obstetric haemorrhage – an observational study. Transfus Med. 2012; 22(5): 344–9.\n\n 1", "score": 0.6018984 }, { "number": 10, "title": "Tranexamic acid for preventing postpartum blood loss after ...", "detail": "obgyn.onlinelibrary.wiley.com", "url": "https://obgyn.onlinelibrary.wiley.com/doi/10.1111/aogs.12798", "authors": "obgyn.onlinelibrary.wiley.com", "host": "obgyn.onlinelibrary.wiley.com", "snippet": "Women who received TXA had significantly less postpartum blood loss, a lower drop in hemoglobin and a lower incidence of postpartum hemorrhage", "score": 0.49685127 }, { "number": 11, "title": "The Use of Tranexamic Acid to Prevent Postpartum ...", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/full/10.1111/jmwh.13101", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com", "snippet": "by RT Mielke · 2020 · Cited by 30 — Evidence suggests that TXA used prophylactically in the setting of cesarean birth may decrease blood loss and the incidence of PPH. There is ...Read more", "score": 0.4574039 }, { "number": 12, "title": "Women receiving massive transfusion due to postpartum ...", "detail": "obgyn.onlinelibrary.wiley.com", "url": "https://obgyn.onlinelibrary.wiley.com/doi/10.1111/aogs.13542", "authors": "obgyn.onlinelibrary.wiley.com", "host": "obgyn.onlinelibrary.wiley.com", "snippet": "Case fatality rate for women who received massive transfusion due to postpartum hemorrhage was 2.3% (4/176) between 2011 and 2012, compared with", "score": 0.40147716 }, { "number": 13, "title": "FIGO recommendations on the management of postpartum ...", "detail": "obgyn.onlinelibrary.wiley.com", "url": "https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116", "authors": "obgyn.onlinelibrary.wiley.com", "host": "obgyn.onlinelibrary.wiley.com", "snippet": "by MF Escobar · 2022 · Cited by 623 — Early use of intravenous tranexamic acid as soon as PPH is diagnosed but within 3 h of birth in addition to standard care is recommended for ...Read more", "score": 0.274753 }, { "number": 14, "title": "Secondary Postpregnancy Hemorrhage: Guide for Diagnosis and ...", "detail": "pubs.rsna.org", "url": "https://pubs.rsna.org/doi/10.1148/rg.240098", "authors": "pubs.rsna.org", "host": "pubs.rsna.org", "snippet": "Primary PPH occurs in the first 24 hours, and causes include uterine atony, uterine rupture or inversion, retained or residual products of", "score": 0.4413124 }, { "number": 15, "title": "Imaging of Antepartum and Postpartum Hemorrhage - RSNA Journals", "detail": "pubs.rsna.org", "url": "https://pubs.rsna.org/doi/10.1148/rg.230164", "authors": "pubs.rsna.org", "host": "pubs.rsna.org", "snippet": "Common causes of PPH that the authors discuss include uterine atony, puerperal genital hematomas, uterine rupture and dehiscence, retained products of", "score": 0.3665676 }, { "number": 16, "title": "Imaging of Antepartum and Postpartum Hemorrhage", "detail": "pubs.rsna.org", "url": "https://pubs.rsna.org/doi/abs/10.1148/rg.230164", "authors": "pubs.rsna.org", "host": "pubs.rsna.org", "snippet": "by K Melamud · 2024 · Cited by 15 — Common causes of PPH that the authors discuss include uterine atony, puerperal genital hematomas, uterine rupture and dehiscence, retained products of ...Read more", "score": 0.35985944 }, { "number": 17, "title": "Interventional Radiology and Pregnancy: From Conception ...", "detail": "pubs.rsna.org", "url": "https://pubs.rsna.org/doi/pdf/10.1148/rg.230029", "authors": "pubs.rsna.org", "host": "pubs.rsna.org", "snippet": "by J Moirano · 2023 · Cited by 10 — Postpartum hemorrhage (PPH) is the most common cause of morbidity and mortality during childbirth (66).", "score": 0.26754585 }, { "number": 18, "title": "Evidence-to-decision framework: treatment bundles for postpartum haemorrhage - WHO recommendations on the assessment of postpartum blood loss and use of a treatment bundle for postpartum haemorrhage - NCBI Bookshelf", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK598983", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov", "snippet": "This bundle included universal risk assessments for PPH, early identification of PPH through quantitative measurement of blood loss, mandatory involvement of a multidisciplinary team at certain blood loss thresholds and point-of-care coagulation testing after 1000-ml blood loss.\n Women with vaginal ", "score": 0.6260562 }, { "number": 19, "title": "Haemostatic monitoring during postpartum haemorrhage and implications for management - PMC", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3498756", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "and interpretation of these tests, we can make better use of their emergency diagnostic capabilities and increase our understanding of the most appropriate haemostatic interventions for the management of obstetric bleeding. Data regarding the efficacy of haemostatic therapies in PPH are sparse. Stud", "score": 0.55912215 }, { "number": 20, "title": "Postpartum Hemorrhage - StatPearls - NCBI Bookshelf - NIH", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK499988", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov", "snippet": "Postpartum hemorrhage (PPH) poses a significant risk to maternal health and is characterized by excessive blood loss after delivery. While uterine contractions and the coagulation cascade primarily regulate blood loss, PPH can lead to severe complications if untreated. Based on blood loss thresholds", "score": 0.5521781 }, { "number": 21, "title": "Management of Postpartum Haemorrhage", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9885818", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "### Management of Hypofibrinogenaemia\n\nFibrinogen levels should be monitored as soon as possible either by standard laboratory tests or ROTEM/TEG in severe ongoing PPH. The decrease in fibrinogen is an early predictor of the severity of PPH and poor outcome. A plasma fibrinogen level <2 g L−1 thresh", "score": 0.5425973 }, { "number": 22, "title": "FIGO recommendations on the management of postpartum ... - PMC", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9313855", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "#### Fibrinogen and cryoprecipitate\n\n11.2.8\nIn hemorrhages, fibrinogen is the first clotting factor to diminish its concentrations to critical levels, with values of <200 mg/dl considered an indication for component replacement.9, 12 Achieving specific fibrinogen levels is an important target during", "score": 0.542161 }, { "number": 23, "title": "Clinical value of early viscoelastometric point‐of‐care testing during ...", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8453832", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "Positive predictive values for progression to severe postpartum hemorrhage for FIBTEM A5 ≤12 mm was 22.5% (95% CI 14–33) and 50% (95% CI 25–75) for fibrinogen", "score": 0.5405607 }, { "number": 24, "title": "Recommendations and supporting evidence - Consolidated guidelines for the prevention, diagnosis and treatment of postpartum haemorrhage - NCBI Bookshelf", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK619233", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov", "snippet": "This recommendation is based on a meta-analysis of individual participant data including over 300 000 women from 12 datasets across 23 countries (28), offering moderate-certainty, individual-level evidence with global representativeness. The findings show that a threshold of ≥300 mL blood loss combi", "score": 0.528899 } ], "publishedAt": "2026-09-15T21:38:34.719482+00:00", "updatedAt": "2026-09-15T21:38:34.719482+00:00", "readingMinutes": 7, "slug": "postpartum-hemorrhage-treatment-sequence" }